Who
Kenneth Bate
Director
Company insider
Files Form 4 as: Director, Astria Therapeutics; Director, Madrigal Pharmaceuticals; Director, Aveo Pharmaceuticals; Director, Epizyme; Director, Genocea Biosciences; Director, Vanda Pharmaceuticals; Director, BioMarin Pharmaceutical; Director, Cubist Pharmaceuticals.
In numbers
- Trades disclosed
- 226
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $29.5M
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 20 Mar 2006
- Last trade
- 23 Jan 2026
- Last filed
- 23 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,666 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,333 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,666 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —8,333 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,550 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —26,550 | filing |
| 5 Nov 2025filed 7 Nov 2025 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,470 at $0.00 | filing |
| 5 Nov 2025filed 7 Nov 2025 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 5 Nov 2025filed 7 Nov 2025 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,105 at $0.00 | filing |
| 5 Nov 2025filed 7 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $52K5,470 at $9.45 | filing |
| 5 Nov 2025filed 7 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $3.0M10,000 at $303.79 | filing |
| 5 Nov 2025filed 7 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $309K1,105 at $280.04 | filing |
| 5 Nov 2025filed 7 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $847K1,763 at $480.24 | filing |
| 5 Nov 2025filed 7 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.6M3,259 at $481.13 | filing |
| 5 Nov 2025filed 7 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $619K1,284 at $482.41 | filing |
| 5 Nov 2025filed 7 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.0M2,069 at $483.41 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)MDGL · themarketsdaily.com · 20 Oct 2026Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)MDGL · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Kenneth Bate; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.